NM_000138.4(FBN1):c.6163+2dup AND not provided

Clinical significance:Uncertain significance (Last evaluated: Aug 4, 2017)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_000138.4(FBN1):c.6163+2dup]


FBN1:fibrillin 1 [Gene - OMIM - HGNC]
Variant type:
Cytogenetic location:
Genomic location:
Preferred name:
  • NC_000015.10:g.48441719dup
  • NG_008805.2:g.209070dup
  • NM_000138.4:c.6163+2dup
  • LRG_778t1:c.6163+2dup
  • LRG_778:g.209070dup
  • NC_000015.9:g.48733915_48733916insA
  • NC_000015.9:g.48733916dup
  • NM_000138.4:c.6163+2dupT
dbSNP: rs794728315
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_000138.4:c.6163+2dup - splice donor variant - [Sequence Ontology: SO:0001575]


MedGen: CN517202

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV000695577Women's Health and Genetics/Laboratory Corporation of America, LabCorpcriteria provided, single submitter
Uncertain significance
(Aug 4, 2017)
germlineclinical testing

LabCorp Variant Classification Summary - May 2015.docx

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000695577.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided


Variant summary: The FBN1 c.6163+2dupT variant involves the alteration of a conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict a significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant of interest has not been found in a large, broad control population, ExAC in 121310 control chromosomes. In addition, one clinical diagnostic laboratory classified this variant as pathogenic. The variant of interest has not, to our knowledge, been reported in affected individuals via publications, nor evaluated for functional impact by in vivo/vitro studies. Considering the in-silico predictions and the potential of this variant to destroy the canonical splice donor site in intron 50, thus affecting gene splicing, this variant is classified as possibly pathogenic, until more functional and clinical studies become available.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jun 14, 2021

Support Center